Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award
31 Octubre 2024 - 6:00AM
Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a
company pioneering a single-molecule protein analysis platform for
quantifying the proteome, today announced Nautilus co-founder and
Chief Scientist Parag Mallick, Ph.D., was bestowed the 2024
Distinguished Investigator (DI) Award by the Academy for Radiology
and Biomedical Imaging Research (the Academy).
The Award recognizes Dr. Mallick’s notable
achievements in the field of imaging research, including his
decades-long leadership, high-impact publications, and ongoing
research and development contributions.
“Innovation in imaging science is essential for
advancing biomedicine,” said Dr. Mallick. “I am truly honored to
receive this prestigious award from the Academy and join its
Council of Distinguished Investigators. This honor is a testament
to the advances my lab members, partners, and colleagues have
helped make possible.”
“Parag continues to prove his unwavering commitment
to scientific excellence and the improvement of human health,” said
Sujal Patel, Chief Executive Officer of Nautilus. “His
accomplishments over the course of his career are many, with each
bringing our entire industry a step closer to unlocking critical
biological insights.”
Dr. Mallick will be inducted into the Academy’s
Council of Distinguished Investigators during the Annual Meeting of
the Radiological Society of North America (RSNA) taking place
December 1-5, 2024 in Chicago, Illinois.
About Nautilus Biotechnology,
Inc.With its corporate headquarters in Seattle and its
research and development headquarters in the San Francisco Bay
Area, Nautilus is a development stage life sciences company
creating a platform technology for quantifying and unlocking the
complexity of the proteome. Nautilus’ mission is to transform the
field of proteomics by democratizing access to the proteome and
enabling fundamental advancements across human health and medicine.
To learn more about Nautilus, visit www.nautilus.bio.
Media
Contactpress@nautilus.bio
Investor
Contactinvestorrelations@nautilus.bio
A photo accompanying this announcement is available
at
https://www.globenewswire.com/NewsRoom/AttachmentNg/84c13f25-a6f3-47cf-a095-6c16525647c7
Nautilus Biotechnology (NASDAQ:NAUT)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Nautilus Biotechnology (NASDAQ:NAUT)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024